Ibogaine acts at the nicotinic acetylcholine receptor cation channel to inhibit catecholamine release
Mechanisms In vitro low
AI-extracted · unverified · confirm at source
MECHANISM: Low-dose ibogaine (10µM) selectively inhibits nicotinic receptor-mediated catecholamine release without affecting K+ or veratridine-evoked release. Not kappa-opioid mediated. Concentration-dependent reversibility.
Dosing: 1–100 µM ibogaine (chromaffin cell culture) (not-specified)